GlassScriptPhysician profile
Lauren Hitt
NPI 1053760850
$4,548.93
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,707 · 2022: $675 · 2023: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,251.11 | 2021-2023 | |
| Incyte Corporation | $287.69 | 2021 | |
| Amgen INC. | $275.75 | 2021-2022 | |
| Exelixis INC. | $264.00 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $240.50 | 2021-2022 | |
| Beigene USA, INC. | $205.32 | 2021-2022 | |
| Daiichi Sankyo INC. | $172.71 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $147.46 | 2021 | |
| Eisai INC. | $143.63 | 2021-2022 | |
| Janssen Biotech, INC. | $142.39 | 2021-2022 | |
| Seagen INC. | $126.90 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $117.61 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $110.71 | 2021-2022 | |
| Lilly USA, LLC | $96.55 | 2021 | |
| Emd Serono, INC. | $82.33 | 2021-2022 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $79.57 | 2021-2022 | |
| Genentech USA, INC. | $65.94 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.73 | 2021 | |
| Acceleron Pharma, INC. | $65.62 | 2021 | |
| Puma Biotechnology, INC. | $65.59 | 2021-2022 | |
| Genzyme Corporation | $64.31 | 2021 | |
| Pfizer INC. | $61.57 | 2021 | |
| Karyopharm Therapeutics INC. | $34.79 | 2021-2022 | |
| Myovant Sciences INC. | $34.60 | 2021 | |
| Rigel Pharmaceuticals, INC. | $32.65 | 2021 | |
| Abbvie INC. | $31.55 | 2021 | |
| Blueprint Medicines Corporation | $28.91 | 2021 | |
| Kyowa Kirin, INC. | $28.83 | 2021 | |
| Boston Scientific Corporation | $28.73 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $25.52 | 2021 | |
| Celgene Corporation | $23.52 | 2021 | |
| Alexion Pharmaceuticals, INC. | $22.39 | 2021 | |
| Coherus Oncology, INC. | $18.75 | 2021 | |
| Astellas Pharma US INC | $17.10 | 2021 | |
| Emmaus Medical, INC. | $16.70 | 2021 | |
| Dova Pharmaceuticals | $16.24 | 2021 | |
| Array Biopharma INC | $16.22 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.38 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $13.35 | 2021 | |
| Morphosys, US INC. | $11.71 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Hitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.